Clearmind Medicine Inc. (CMND) NASDAQ
2.92
-0.25(-7.89%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Clearmind Medicine Inc.
Address
1220 West 6th Avenue
Vancouver, BC V6H 1A5
Canada
Phone
604 260 1566
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
November 15, 2022
Key Executives
| Name | Title | Pay | Year Born |
| Adi Zuloff-Shani | Chief Executive Officer | 304,773 | 1967 |
| Mark Haden | Vice President of Business Development | 0 | 1953 |
| Alan Mark Rootenberg | Chief Financial Officer | 0 | 1952 |
| Adi Varon | Controller | 0 | N/A |
| Mary-Elizabeth Gifford | Chief of Global Impact | 0 | N/A |
| Mylene Touboul | Accounting Manager | 0 | N/A |
Description
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
